MEI Pharma (MEIP) Competitors $3.19 +0.41 (+14.71%) Closing price 09/10/2025Extended Trading$3.19 0.00 (0.00%) As of 09/10/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MEIP vs. ATYR, AQST, ESPR, IVA, RAPP, CYRX, ZVRA, PRME, BCYC, and EOLSShould you be buying MEI Pharma stock or one of its competitors? The main competitors of MEI Pharma include aTyr Pharma (ATYR), Aquestive Therapeutics (AQST), Esperion Therapeutics (ESPR), Inventiva (IVA), Rapport Therapeutics (RAPP), CryoPort (CYRX), Zevra Therapeutics (ZVRA), Prime Medicine (PRME), Bicycle Therapeutics (BCYC), and Evolus (EOLS). These companies are all part of the "pharmaceutical products" industry. MEI Pharma vs. Its Competitors aTyr Pharma Aquestive Therapeutics Esperion Therapeutics Inventiva Rapport Therapeutics CryoPort Zevra Therapeutics Prime Medicine Bicycle Therapeutics Evolus aTyr Pharma (NASDAQ:ATYR) and MEI Pharma (NASDAQ:MEIP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability. Do analysts rate ATYR or MEIP? aTyr Pharma currently has a consensus target price of $23.25, indicating a potential upside of 2,052.78%. Given aTyr Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe aTyr Pharma is more favorable than MEI Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17MEI Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better valuation & earnings, ATYR or MEIP? MEI Pharma has lower revenue, but higher earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than MEI Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioaTyr Pharma$230K460.13-$64.02M-$0.80-1.35MEI PharmaN/AN/A$17.78M-$4.75-0.67 Do insiders & institutionals have more ownership in ATYR or MEIP? 61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 52.4% of MEI Pharma shares are held by institutional investors. 3.7% of aTyr Pharma shares are held by company insiders. Comparatively, 3.1% of MEI Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is ATYR or MEIP more profitable? MEI Pharma's return on equity of -77.00% beat aTyr Pharma's return on equity.Company Net Margins Return on Equity Return on Assets aTyr PharmaN/A -93.69% -68.83% MEI Pharma N/A -77.00%-64.79% Which has more risk & volatility, ATYR or MEIP? aTyr Pharma has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Does the media prefer ATYR or MEIP? In the previous week, aTyr Pharma had 29 more articles in the media than MEI Pharma. MarketBeat recorded 32 mentions for aTyr Pharma and 3 mentions for MEI Pharma. MEI Pharma's average media sentiment score of 0.27 beat aTyr Pharma's score of 0.05 indicating that MEI Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 3 Very Positive mention(s) 6 Positive mention(s) 9 Neutral mention(s) 7 Negative mention(s) 1 Very Negative mention(s) Neutral MEI Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryaTyr Pharma beats MEI Pharma on 9 of the 14 factors compared between the two stocks. Get MEI Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MEIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MEIP vs. The Competition Export to ExcelMetricMEI PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$104.72M$2.55B$5.73B$10.31BDividend YieldN/A60.31%5.90%4.63%P/E Ratio-0.6723.4975.8626.51Price / SalesN/A672.77528.74123.58Price / Cash0.51169.4937.1760.46Price / Book0.645.3312.796.29Net Income$17.78M$32.95M$3.28B$270.51M7 Day Performance14.71%-0.44%0.22%2.15%1 Month Performance-34.79%3.91%4.61%6.35%1 Year Performance4.56%-3.07%68.33%25.48% MEI Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MEIPMEI Pharma1.4917 of 5 stars$3.19+14.7%N/A+5.2%$104.72MN/A-0.67100Upcoming EarningsGap UpHigh Trading VolumeATYRaTyr Pharma2.4954 of 5 stars$5.46-2.7%$23.25+325.8%-46.8%$549.71M$230K-6.8253Trending NewsAnalyst ForecastGap UpAQSTAquestive Therapeutics2.2738 of 5 stars$5.01-7.6%$10.29+105.3%+6.2%$540.50M$57.56M-7.16160Positive NewsESPREsperion Therapeutics3.7963 of 5 stars$2.51-6.3%$7.00+178.9%+45.5%$540.35M$332.31M-5.12200IVAInventiva3.1489 of 5 stars$5.37-3.6%$14.83+176.2%+137.1%$532.84M$9.95M0.00100Short Interest ↑Gap DownRAPPRapport Therapeutics3.0763 of 5 stars$31.47+119.2%$31.00-1.5%+30.2%$524.11MN/A-12.59N/AAnalyst UpgradeGap UpHigh Trading VolumeCYRXCryoPort3.9856 of 5 stars$10.04-3.0%$12.00+19.5%+5.0%$518.19M$228.38M7.551,186News CoveragePositive NewsZVRAZevra Therapeutics2.9893 of 5 stars$8.33-6.9%$23.71+184.7%-7.9%$502.41M$23.61M-39.6720News CoveragePositive NewsAnalyst DowngradeGap UpPRMEPrime Medicine3.3188 of 5 stars$3.89+4.6%$8.92+129.2%-2.0%$500.62M$4.96M-1.90234BCYCBicycle Therapeutics3.5041 of 5 stars$7.00-2.2%$22.22+217.5%-74.6%$495.86M$35.28M-1.99240Positive NewsEOLSEvolus4.052 of 5 stars$7.61-0.7%$21.25+179.2%-62.1%$495.49M$266.27M-7.77170 Related Companies and Tools Related Companies aTyr Pharma Alternatives Aquestive Therapeutics Alternatives Esperion Therapeutics Alternatives Inventiva Alternatives Rapport Therapeutics Alternatives CryoPort Alternatives Zevra Therapeutics Alternatives Prime Medicine Alternatives Bicycle Therapeutics Alternatives Evolus Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MEIP) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MEI Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MEI Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MEIP Stock Alerts